Abstract
Aicardi Goutieres Syndrome (AGS) is characterized by mutations occurring in genes encoding RNAses. AGS mutations silence intracellular RNases resulting in an intracellular overload of short RNAs arresting the physiological production of microRNA required for brain development. MiR-219 is typically down-regulated in Aicardi Goutieres Syn-drome (AGS). The goal of this study is to investigate miR-219 role in protecting astrocytes co-cultured with AGS-mutated lymphocytes. These lymphocytes display neurotoxic properties due to the presence of AGS-mutation and to their activa-tion by interpheron-alpha (IFN). Obtained results provide the evidence that astrocytes transfected with microRNA-219 are protected from the neurotoxic action of AGS lymphocytes activated by IFN-alpha. In particular, the miR-219 transfection increased astrocyte viability, growth, and differentiation while decreasing cell necrosis and apoptosis. Thus, microRNA-219 transfection is a valuable strategy in order to confer resistance to astrocytes towards lymphocyte-induced neurotoxici-ty especially in the presence of IFN-alpha, whose levels are typically increased in the cerebrospinal fluid of AGS patients.
Keywords: Aicardi Goutieres Syndrome, interferon-alpha, lymphocytes, microRNA, miR-219 transfection, neurotoxicity.
MicroRNA
Title:Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery
Volume: 2 Issue: 3
Author(s): Alessandra Pulliero, Barbara Marengo, Daniela Fenoglio, Alessia Parodi, Cristina Cereda, Cinzia Domenicotti, Simona Orcesi, Jessica Galli, Ivana Olivieri, Gilberto Filaci, Umberto Balottin, Elisa Fazzi and Alberto Izzotti
Affiliation:
Keywords: Aicardi Goutieres Syndrome, interferon-alpha, lymphocytes, microRNA, miR-219 transfection, neurotoxicity.
Abstract: Aicardi Goutieres Syndrome (AGS) is characterized by mutations occurring in genes encoding RNAses. AGS mutations silence intracellular RNases resulting in an intracellular overload of short RNAs arresting the physiological production of microRNA required for brain development. MiR-219 is typically down-regulated in Aicardi Goutieres Syn-drome (AGS). The goal of this study is to investigate miR-219 role in protecting astrocytes co-cultured with AGS-mutated lymphocytes. These lymphocytes display neurotoxic properties due to the presence of AGS-mutation and to their activa-tion by interpheron-alpha (IFN). Obtained results provide the evidence that astrocytes transfected with microRNA-219 are protected from the neurotoxic action of AGS lymphocytes activated by IFN-alpha. In particular, the miR-219 transfection increased astrocyte viability, growth, and differentiation while decreasing cell necrosis and apoptosis. Thus, microRNA-219 transfection is a valuable strategy in order to confer resistance to astrocytes towards lymphocyte-induced neurotoxici-ty especially in the presence of IFN-alpha, whose levels are typically increased in the cerebrospinal fluid of AGS patients.
Export Options
About this article
Cite this article as:
Pulliero Alessandra, Marengo Barbara, Fenoglio Daniela, Parodi Alessia, Cereda Cristina, Domenicotti Cinzia, Orcesi Simona, Galli Jessica, Olivieri Ivana, Filaci Gilberto, Balottin Umberto, Fazzi Elisa and Izzotti Alberto, Prevention of Lymphocyte Neurotoxic Effects by microRNA Delivery, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/22115366113029990010
DOI https://dx.doi.org/10.2174/22115366113029990010 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Control of Male Sexual Responses
Current Pharmaceutical Design From The Editors Perspective: Unlocking the Secrets to Cell Survival and Longevity
Current Neurovascular Research Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Comparison of Status Epilepticus Models Induced by Pilocarpine and Nerve Agents - A Systematic Review of the Underlying Aetiology and Adopted Therapeutic Approaches
Current Medicinal Chemistry Hydrogen Sulfide Generation in Mammals: The Molecular Biology of Cystathionine-β-Synthase (CBS) and Cystathionine-γ-Lyase (CSE)
Inflammation & Allergy - Drug Targets (Discontinued) Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Stem Cells in Skeletal Tissue Engineering: Technologies and Models
Current Stem Cell Research & Therapy Selective Pharmacological Inhibition of the Pacemaker Channel Isoforms (HCN1-4) as New Possible Therapeutical Targets
Current Medicinal Chemistry Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Curcuminoids in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Role of Fibroblast Growth Factor Receptors in Astrocytic Stem Cells
Current Signal Transduction Therapy Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry